Insider Selling: Tango Therapeutics (NASDAQ:TNGX) Insider Sells $157,635.02 in Stock

Tango Therapeutics, Inc. (NASDAQ:TNGX) insider Jessica Newcomb sold 7,031 shares of the firm’s stock in a transaction dated Monday, November 2nd. The shares were sold at an average price of $22.42, for a total value of $157,635.02. Following the completion of the transaction, the insider owned 52,090 shares in the company, valued at approximately $1,167,857.80. This represents a 11.89% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Jessica Newcomb also recently made the following trade(s):

• On Tuesday, September 22nd, Jessica Newcomb sold 8,200 shares of Tango Therapeutics stock. The stock was sold at an average price of $24.22, for a total value of $198,604.00.

Tango Therapeutics Price Performance

Shares of NASDAQ TNGX opened at $21.50 on Friday. The firm has a 50-day simple moving average of $23.34 and a two-hundred day simple moving average of $22.48. Tango Therapeutics, Inc. has a 1 year low of $7.37 and a 1 year high of $34.39.

Tango Therapeutics (NASDAQ:TNGX) last issued its earnings results on Tuesday, August 11th. The company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.32) by ($0.05). On average, sell-side analysts expect that Tango Therapeutics, Inc. will post -1.41 EPS for the current fiscal year.

Wall Street Analyst Weigh In

TNGX has been the topic of several research analyst reports. JPMorgan Chase & Co. began coverage on shares of Tango Therapeutics in a research report on Wednesday, July 15th. They issued an “overweight” rating and a $46.00 target price on the stock. Stifel Nicolaus set a $55.00 price objective on Tango Therapeutics in a report on Friday, October 23rd. Weiss Ratings upgraded Tango Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, August 11th. HC Wainwright reiterated a “buy” rating and issued a $68.00 price target on shares of Tango Therapeutics in a research note on Thursday, October 29th. Finally, Mizuho boosted their price target on shares of Tango Therapeutics from $36.00 to $40.00 and gave the company an “outperform” rating in a report on Friday, July 17th. Thirteen investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $44.62.

Institutional Investors Weigh In On Tango Therapeutics

Several institutional investors have recently bought and sold shares of TNGX. Nykredit A S purchased a new position in Tango Therapeutics in the second quarter worth $26,000. Allworth Financial LP purchased a new position in Tango Therapeutics in the second quarter valued at about $35,000. Global Retirement Partners LLC purchased a new stake in shares of Tango Therapeutics during the 2nd quarter valued at about $122,000. Sterling Capital Management LLC raised its holdings in shares of Tango Therapeutics by 838.8% during the third quarter. Sterling Capital Management LLC now owns 4,647 shares of the company’s stock valued at $116,000 after acquiring an additional 4,152 shares during the period. Finally, State of Wyoming bought a new stake in Tango Therapeutics in the first quarter valued at $128,000. Institutional investors own 78.99% of the company’s stock.

Tango Therapeutics Company Profile

Tango Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing medicines for cancer. The company uses functional genomics and genetic screening to identify vulnerabilities in tumor cells, including dependencies created by tumor-suppressor gene loss, and to develop targeted therapies designed to selectively attack cancer cells.

Tango’s pipeline includes small-molecule programs for genetically defined solid tumors. Its lead program, TNG462, is an MTA-cooperative PRMT5 inhibitor being developed for cancers with MTAP gene deletions.